Xbrane Biopharma Q4 2024: Initial take – soft - Redeye

Redeye’s comments on Xbrane following its year-end report, which showed negative revenue growth both y/y and q/q. The report also included an unexpected writedown of the milestone payment from Biogen and the upfront payment from Valorum Biologics. We anticipate lowering our fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1080962/xbrane-biopharma-q4-2024-initial-take-soft?utm_source=finwire&utm_medium=RSS